Holding(s) in Company

Rhea-AI Summary

On October 9, 2020, Amryt Pharma PLC received notification from UBS Asset Management, indicating a significant change in voting rights. UBS's holdings dropped from 6.13% to 6.12%, with the date of the threshold crossed being October 7, 2020. The report stated that UBS held a total of 162,801,593 voting rights, with 9,967,620 of those rights derived from financial instruments. This notification reflects a minor adjustment in UBS's position but retains their significant interest in the company.

Positive

• UBS Asset Management holds 6.12% of voting rights, indicating continued significant interest.
• Total voting rights amount to 162,801,593, showcasing healthy shareholder engagement.

Negative

• Slight decrease in voting rights from previous 6.13% to 6.12%, which may reflect a diminishing confidence.
• UBS's holdings are below a threshold, potentially affecting influence over company decisions.

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Amryt Pharma PLC GB00BKLTQ412

1b. Please indicate if the issuer is a non-UK issuer  (please mark with an “X” if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an “X”)

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

X

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

UBS Asset Management - O'Connor UBS Group AG

City and country of registered office (if applicable)

Zürich, Switzerland

4. Full name of shareholder(s) (if different from 3.)v

Name

UBS O'Connor LLC

City and country of registered office (if applicable)

Wilmington, USA

5. Date on which the threshold was crossed or reachedvi:

7 October 2020

6. Date on which issuer notified (DD/MM/YYYY):

9 October 2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

-

6.12%

6.12%

162’801’593

Position of previous notification (if applicable)

2.60%

3.53%

6.13%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type of shares ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BKLTQ412

-

-

SUBTOTAL 8. A

-

-

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expiration datex

Exercise/ Conversion Periodxi

Number of voting rights that may be acquired if the instrument is exercised/converted.

% of voting rights

US03217L1061

9’967’620

6.12%

SUBTOTAL 8. B 1

9’967’620

6.12%

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration datex

Exercise/ Conversion Period xi

Physical or cash settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)				X
Namexv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
UBS Group AG
UBS AG
UBS Americas Holding LLC
UBS Americas Inc
UBS Asset Management (Americas) Inc
UBS O'Connor LLC	-	6.12%	6.12%

10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional informationxvi

Place of completion	Opfikon, Switzerland
Date of completion	09.10.2020

FAQ

What recent changes occurred in UBS Asset Management's holdings in Amryt Pharma?

UBS Asset Management's holdings in Amryt Pharma dropped from 6.13% to 6.12% as of October 7, 2020.

When was Amryt Pharma notified about UBS's change in voting rights?

Amryt Pharma was notified on October 9, 2020.

What is the current percentage of voting rights held by UBS Asset Management?

UBS Asset Management currently holds 6.12% of the voting rights in Amryt Pharma.

How many total voting rights does Amryt Pharma have?

Amryt Pharma has a total of 162,801,593 voting rights.

What types of holdings contributed to UBS's voting rights percentage in Amryt Pharma?

UBS's voting rights percentage includes both direct and financial instrument holdings.